In May 2025, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) plans to vote on whether to add Duchenne to the Recommended Uniform Screening Panel (RUSP) for newborn screening. To support a push for evidence about the impact of early diagnosis on outcomes prior to the vote, PPMD recently hosted the Duchenne Early Intervention Symposium. Seven researchers presented projects that assessed outcomes in patients treated earlier than the average age of diagnosis, which is between 4-5 years of age.